TARS - Tarsus Pharmaceuticals, Inc. News

Alkeus Pharmaceuticals Receives Orphan Drug Designation From Japan's Ministry Of Health, Labour, And

Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of indiv

Alkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orp

CAMBRIDGE, Mass., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutica

Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100

Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outp

marketbeat.com

Tarsus Pharmaceuticals Q2 Earnings Call Highlights

Tarsus Pharmaceuticals NASDAQ: TARS reported second-quarter growth in sales of its Demodex blepharit

Tarsus Pharmaceuticals Q2 EPS $(0.43) Misses $(0.20) Estimate, Sales $173.912M Beat $169.677M Estima

Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.43) per share which missed the

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.43 per share versus the Zac

Tarsus Pharmaceuticals To Acquire Alkeus Pharmaceuticals, A Closely Held Biotech Firm Developing Gil

Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

Generated second quarter 2026 XDEMVY ® net product sales of $173.9 million, an increase of more than

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (“Tars

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral

Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

IRVINE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today

Mizuho Maintains Outperform on Tarsus Pharmaceuticals, Lowers Price Target to $98

Mizuho analyst Graig Suvannavejh maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform

Tarsus Pharmaceuticals, Inc. (TARS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a

defenseworld.net

Caxton Associates LLP Has $1.06 Million Holdings in Tarsus Pharmaceuticals, Inc. $TARS

Caxton Associates LLP cut its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) by 6

Tarsus Pharmaceuticals: Q2 2026 Rebound In Sales Possible, Catalysts Approaching

TARS experienced a dip in net product sales in Q1'26, relative to Q4'25, the first decrease since Xd

Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Lowers Price Target to $89

Guggenheim analyst Brad Canino maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and lowe

Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of G

IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today

marketbeat.com

Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline

Tarsus Pharmaceuticals NASDAQ: TARS said it has closed its acquisition of iRenix Medical, Inc., addi

Tarsus Buys iRenix in Deal Worth Up to $565 Million, Adds Late-Stage Eye Drug

Tarsus Pharmaceuticals Inc. (NASDAQ:TARS) on Wednesday acquired privately held iRenix Medical Inc.,

Tarsus Buys iRenix in Deal Worth Up to $565 Million, Adds Late-Stage Eye Drug

Tarsus acquires iRenix to add IRX-101, with Phase 3 planned for 2027, as William Blair calls the dea

HC Wainwright & Co. Reiterates Buy on Tarsus Pharmaceuticals, Maintains $88 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Tarsus Pharmaceuticals (NASDAQ:TARS)

Tarsus Pharmaceuticals, Inc. (TARS) M&A Call Transcript

Tarsus Acquires iRenix Medical And Late-Stage Asset IRX-101 For ~$75M

IRX-101 targets a significant need for millions of patients facing vision loss and has the potential

Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset

IRX-101 targets a significant need for millions of patients facing vision loss and has the potential

All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to Buy

Tarsus Pharmaceuticals (TARS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimis

Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?

Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. Th

Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) shares are falling Wednesday. Short-seller Culper Research

Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today

Tarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance Raise

Tarsus Pharmaceuticals (TARS) is reiterated as a Strong Buy, with a 12-month price target of $95 per

Tarsus Pharmaceuticals Collaborates With John Cena Over Eyelid Disease Demodex Blepharitis

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced a new partnership with John Cena to rais

Earnings Scheduled For May 6, 2026

HC Wainwright & Co. Reiterates Buy on Tarsus Pharmaceuticals, Maintains $88 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Tarsus Pharmaceuticals (NASDAQ:TARS)

Tarsus Pharma Says First Participant Dosed In Phase 2 Clinical Trial Evaluating TP-05, Investigation

– A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks befor

Tarsus Pharmaceuticals Announces $15M Milestone Payment Achieved After Regulatory Approval Of TP-03

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due

Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $105

Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outp

Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $90

Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and ra

Henry Schein, Vir Biotechnology, Ultra Clean Holdings And Other Big Stocks Moving Higher On Tuesday

Tarsus Pharmaceuticals Q4 EPS $(0.20) Misses $(0.11) Estimate, Sales $151.668M Beat $144.565M Estima

Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.20) per share which missed the

Insights into Tarsus Pharmaceuticals Q4 Earnings

Earnings Scheduled For February 23, 2026

Earnings Preview: Tarsus Pharmaceuticals

Barclays Initiates Coverage On Tarsus Pharmaceuticals with Overweight Rating, Announces Price Target

Barclays analyst Glen Santangelo initiates coverage on Tarsus Pharmaceuticals (NASDAQ:TARS) with

Mizuho Initiates Coverage On Tarsus Pharmaceuticals with Outperform Rating, Announces Price Target o

Mizuho analyst Graig Suvannavejh initiates coverage on Tarsus Pharmaceuticals (NASDAQ:TARS) with

Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $87

Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and ra

Tarsus Pharmaceuticals Q3 EPS $(0.30) Beats $(0.38) Estimate, Sales $118.697M Beat $115.222M Estimat

Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.30) per share which beat the a

Earnings Scheduled For November 4, 2025

HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $88

HC Wainwright & Co. analyst Matthew Caufield maintains Tarsus Pharmaceuticals (NASDAQ:TARS) w

Top 2 Health Care Stocks That May Fall Off A Cliff In August